Research programme: lysosomal acid lipase - Large Scale Biology Corporation

Drug Profile

Research programme: lysosomal acid lipase - Large Scale Biology Corporation

Latest Information Update: 20 Feb 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Cincinnati
  • Developer Large Scale Biology Corporation (CEASED)
  • Class Cardiovascular therapies
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Atherosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 23 Dec 2005 Large Scale Biology Corporation ceased operations
  • 23 Sep 2005 Large Scale Biology Corporation and Icon Genetics announced the initiation of the commercial phase of their collaborative agreement for an undisclosed product for enzyme replacement therapy
  • 01 Aug 2005 Lysosomal acid lipase has received orphan drug status in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top